Meridian Small Cap Growth Fund
MSGRX
NASDAQ- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 100 Fillmore Street Denver CO United States of America 80206
- IPO Date
- Dec 24, 2014
- CIK
- 0000745467
- Website
- arrowmarkpartners.com
- Similar Companies
- Business
- Meridian Small Cap Growth Fund (MSGRX) is an open-end mutual fund that seeks long-term growth of capital primarily through investments in equity securities of U.S. small-capitalization growth companies; it employs a research-driven process emphasizing high-quality firms with differentiated business models, strong competitive advantages, large barriers to entry, and downside protection. The fund offers multiple share classes including Institutional (MSGRX), Investor (MISGX), Class A (MSGAX), Class C (MSGCX), and Legacy (MSGGX), with a minimum initial investment of $1,000,000 for Institutional shares; it benchmarks performance against the Russell 2000 Growth Index and maintains a portfolio of approximately 97 holdings focused on sectors such as technology, consumer cyclical, industrials, and consumer defensive, with top holdings including Consensus Cloud Solutions Inc., Turning Point Brands Inc., and CarGurus Inc. Managed by co-portfolio managers Chad Meade and Brian Schaub since inception, the fund targets small-growth companies generally under $5 billion in market capitalization, with weighted-average market cap around $2.7 billion as of September 2025; it operates within the small growth category, serving qualified institutional investors and certain platforms, with total net assets of approximately $358-428 million. Headquartered in Denver, Colorado under advisor ArrowMark Colorado Holdings LLC (ArrowMark Partners), a privately held employee-owned investment management firm founded in 2007, the fund traces its inception to December 16, 2013, and focuses exclusively on U.S. markets without significant foreign exposure. In recent developments, ArrowMark Partners reopened the Meridian Small Cap Growth Fund to new investors in October 2024 following a closure in 2018 due to capacity limits, reflecting sustained demand after a period of soft returns; the firm also broadened employee ownership to 17 staff members, reducing founder David Corkins' stake below 50% to support long-term stability. During the third quarter of 2025, the fund trimmed its position in Zenas BioPharma amid share price appreciation and positive developments including a non-dilutive funding agreement worth up to $300 million with Alnylam Pharma to advance clinical trials for Obelimab, aligning with its prudent valuation discipline.